Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients

Cancer Immunology, Immunotherapy

Volumn 64, Issue 7, 2015, Pages 805-815

  Khammari, Amir ^a,b   Nguyen, Jean Michel ^b,c   Saint Jean, Melanie ^a,b   Knol, Anne Chantal ^b   Pandolfino, Marie Christine ^a,b   Quereux, Gaelle ^a,b   Brocard, Anabelle ^a,b   Peuvrel, Lucie ^a,b   Saiagh, Soraya ^a   Bataille, Vincent ^d   Limacher, Jean Marc ^d   Dreno, Brigitte ^a,b  

^a Nantes Hospital   (France)

^b Team 12   (France)

^c CHU DE NANTES   (France)

^d TRANSGENE S A   (France)

Author keywords

Adoptive T cell therapy; Interferon ; Melanoma; TG1042

Indexed keywords

ALDESLEUKIN; CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON DERIVATIVE; TG 1042; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T LYMPHOCYTE THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; CANCER STAGING; CLINICAL ARTICLE; DISEASE CONTROL; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALE; MELANOMA CELL LINE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA AND VOMITING; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SKIN METASTASIS; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; VIRUS PARTICLE; ADENOVIRIDAE; BIOLOGICAL THERAPY; CLINICAL TRIAL; GENE THERAPY; GENETICS; IMMUNOLOGY; MELANOMA; MULTIMODALITY CANCER THERAPY; PROCEDURES; TRANSPLANTATION; TUMOR CELL LINE; TUMOR ESCAPE;

ADENOVIRIDAE; ADULT; AGED; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; FEMALE; GENETIC THERAPY; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR ESCAPE;

EID: 84933182475     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1691-7     Document Type: Article

References (30)

1. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281
2. Kirkwood JM, Ernstoff MS (1990) Role of interferons in the therapy of melanoma. J Invest Dermatol 95:180S–184S
3. Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, Bruce J, Ognoskie N, Wynne D, Pike M, Kowal K, Merritt J, Ando D (1999) Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 6:322–330
4. Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Landrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K (2003) A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10:251–259
5. Whittington R, Faulds D (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446–514
6. Bachmann MF, Oxenius A (2007) Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8:1142–1148
7. Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, Straten PT, Svane IM (2013) Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol 133:545–552
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
9. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, LeMevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405–411
10. Pandolfino MC, Labarriere N, Tessier MH, Cassidanius A, Bercegeay S, Lemarre P, Dehaut F, Dreno B, Jotereau F (2001) High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol Immunother 50:134–140
11. Chebassier N, El Houssein O, Viegas I, Dreno B (2004) In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol 13:484–490
12. Jarry A, Masson D, Cassagnau E, Parois S, Laboisse C, Denis MG (2004) Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes 18:349–352
13. Gervois N, Heuze F, Diez E, Jotereau F (1990) Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20:825–831
14. Pandolfino MC, Saiagh S, Knol AC, Dreno B (2010) Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology 62:403–412
15. Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197–207
16. Yang JC (2013) The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clin Dermatol 31:209–219
17. Khammari A, Knol AC, Nguyen JM, Bossard C, Denis MG, Pandolfino MC, Quéreux G, Bercegeay S, Dréno B (2014) Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res 2014:186212. doi:10.1155/2014/186212
18. Pt Straten, Becker JC (2009) Adoptive cell transfer in the treatment of metastatic melanoma. J Invest Dermatol 129:2743–2745
19. Dudley ME (2011) Adoptive cell therapy for patients with melanoma. J Cancer 2:360–362
20. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51:539–546
21. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P, Acres B, Bleuzen P, Bataille V, Squiban P, Burg G, Urosevic M (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104:1631–1638
22. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535–539
23. Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K (1991) Study of tumor infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother 10:313–325
24. Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL (1997) Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. J Immunother 20:146–157
25. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M (2002) Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 51:440–448
26. Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B (2013) Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One 8:e76829
27. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6:409–422
28. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763–5771
29. Dummer R, Rochlitz C, Velu T, Acres B, Limacher JM, Bleuzen P, Lacoste G, Slos P, Romero P, Urosevic M (2008) Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 16:985–994
30. Labarriere N, Fortun A, Bellec A, Khammari A, Dreno B, Saïagh S, Lang F (2013) A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol 2013:932318. doi:10.1155/2013/932318